Clinicaltrials.gov: Rep. Waxman Wants PhRMA To Describe Steps To Improve Compliance
This article was originally published in The Pink Sheet Daily
Executive Summary
Waxman takes issue with PhRMA’s failure to appear at a recent House hearing to discuss FDA’s clinical trial registry. He asks the association to submit documents it has sent to member companies regarding compliance with the submission requirement.
You may also be interested in...
FDA Should Issue Pediatric Antidepressant Trial Summaries, Rep. Waxman Says
The congressman's letter requests the immediate release of data for drugs that gained six months of additional exclusivity under the Best Pharmaceuticals for Children Act. While seven companies have gained exclusivity extensions for antidepressants, data on only two are available, he says.
FDA Should Issue Pediatric Antidepressant Trial Summaries, Rep. Waxman Says
The congressman's letter requests the immediate release of data for drugs that gained six months of additional exclusivity under the Best Pharmaceuticals for Children Act. While seven companies have gained exclusivity extensions for antidepressants, data on only two are available, he says.
FDA Can Post On ClinicalTrials.gov, But Unlikely To Use Authority, Agency Says
Lack of funding and lack of an enforcement mechanism prevent the agency from taking a more active role in ensuring industry compliance with posting requirements. Sens. Johnson and Dodd appear willing to give FDA more enforcement authority.